Verve Therapeutics Inc (VERV)

33.42 -0.66  -1.94% NASDAQ Dec 1, 16:00 32.05 -1.37  -4.10% After-Hours: 18:49 USD

Verve Therapeutics Cash from Financing (TTM):

375.87M for Sept. 30, 2021
View 4,000+ financial data types
View Full Chart

Cash from Financing (TTM) Chart

Export Data
Save Image
Print Image

Historical Cash from Financing (TTM) Data

View and export this data going back to 2020. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
Sept. 30, 2021 375.87M
June 30, 2021 376.74M
March 31, 2021 156.73M
Dec. 31, 2020 92.63M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.


Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Benchmarks

Regenxbio Inc 381.77M
Krystal Biotech Inc 145.75M
Beam Therapeutics Inc 864.59M

Cash from Financing (TTM) Range, Past 5 Years

Minimum 92.63M Dec 2020
Maximum 376.74M Jun 2021
Average 250.49M


Verve Therapeutics' Q3 Net Loss Shrinks
MT Newswires 11/10 07:51 ET
Top IPO additions to Russell 2000 Index
SA Breaking News 09/17 10:48 ET



Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{}} No credit card required.

Already a subscriber? Sign in.